HOME

ABOUT US

• •  Management
• •  Board of Directors
• •  Collaborations

PRODUCT PIPELINE

• •  Brentuximab Vedotin (SGN-35)
• •  Lintuzumab (SGN-33)
• •  Dacetuzumab (SGN-40)
• •  SGN-70
• •  SGN-75
• •  Preclinical Programs
• •  Scientific Publications

TECHNOLOGY

• •  ADC Technology
• •  SEA Technology
• •  Scientific Publications

CLINICAL TRIALS

• •  Brentuximab Vedotin (SGN-35)
• •  Lintuzumab (SGN-33)
• •  Dacetuzumab (SGN-40)
• •  SGN-70
• •  SGN-75

• •  Hodgkin Lymphoma
• •  Non-Hodgkin Lymphoma
• •  Multiple Myeloma
• •  Leukemia/MDS
• •  Autoimmune
• •  Solid Tumors

INVESTORS & NEWS

• •  Press Releases
• •  Stock Performance
• •  SEC Filings
• •  Webcasts & Events
• •  Scientific Publications
• •  Corporate Governance
• •  Analyst Coverage
• •  Financial Reports
• •  Investor FAQ
• •  Information Request

CAREERS

• •  Benefits
• •  Living in the Area
• •  Job Opportunities

GLOSSARY

SITEMAP

CONTACT